Publications

Show all

2021

Nature 2021, 15(2): B24
Engineered neuroreceptor-specificity set to deliver next-generation schizophrenia therapeutics.
Laxminarayan Bhat

Show all

2018

Journal of Neurology and Neuromedicine 2018, 3(5):39-50 (Invited Review)
Brilaroxazine (RP5063) Clinical Experience in Schizophrenia: A New Option to Address Unmet Needs.
Laxminarayan Bhat, Marc Cantillon, and Robert Ings

European Journal of Drug Metabolism and Pharmacokinetics 2018, 43:573-585
A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia 
or Schizoaffective Disorder.
Marc Cantillon, Robert Ings, Arul Prakash, Laxminarayan Bhat

Clinical and Translational Science 2018, 11:387-396
Initial clinical experience of RP5063 following single doses in normal healthy volunteers and multiple doses in patients with stable schizophrenia.
Marc Cantillon, Robert Ings, and Laxminarayan Bhat

Clinical and Translational Science 2018, 11:378-386
Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients.
Marc Cantillon, Robert Ings, and Laxminarayan Bhat

European J Pharmacology 2018, 827:159-166.
Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and 
co-administrated with sildenafil, bosentan, and treprostinil in the monocrotaline-induced pulmonary arterial hypertension rat model.
Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.
Show all

2017

Schizophrenia Research 2017, 189: 126-133.
Dopamine Serotonin Stabilizer RP5063: A Randomized, Double-blind, Placebo-controlled Multicenter Trial of 
Safety and Efficacy in Exacerbation of Schizophrenia or Schizoaffective Disorder.
Marc Cantillon, Arulprakash R, Ajay Alexander, Robert Ings, Dennis Sweitzer, Laxminarayan Bhat

Behavioral Brain Research 2017, 332: 180-199.
RP5063, an atypical antipsychotic drug with a novel mechanism of action, improves cognition and psychosis in mouse models of schizophrenia.
Lakshmi Rajagopal, Sunoh Kwon, Mei Huang, Eric Michael, Laxminaryan Bhat, Marc Cantillon, Herbert Y. Meltzer

Journal of Rare Disease Research & Treatment 2017, 2(5): 5-12 (Invited Review)
A closer look at the preclinical experience of RP5063 in pulmonary arterial hypertension (PAH).
Laxminarayan Bhat and Dany Salvail.

European J Pharmacology 2017, 810: 83-91.
RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-induced pulmonary arterial hypertension in rats.
Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.

European J Pharmacology 2017, 810: 92-99.
RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.